When was Kamui Pharma founded?

Kamui Pharma was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Kamui Pharma located?

Kamui Pharma is headquartered in Asahikawa, Japan.

Is Kamui Pharma a funded company?

Kamui Pharma is a funded company, having raised a total of $130M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2018.

When was the latest funding round of Kamui Pharma?

Kamui Pharma's latest funding was a $***** Series B round on Jul 26, 2022, with participation from 5 investors.

Where does Kamui Pharma rank among its competitors?

Kamui Pharma ranks 55th amongst 139 active competitors, of which 46 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Enveda, which secured $311M in Sep, 2026.

Who are the top competitors of Kamui Pharma?

Kamui Pharma's top competitors include Novozymes, Phathom Pharmaceuticals and OMass Therapeutics. Among them, Enveda secured the most recent funding round in September, 2026.

Kamui Pharma - 2026 Company Profile, Funding & Competitors

Kamui Pharma is a series B company based in Asahikawa (Japan), founded in 2018. It operates as a Developer of probiotic medicines for gastrointestinal diseases. Kamui Pharma has raised $130M in funding from investors like Mitsubishi UFJ Capital, Hokkaido Venture Capital and Cyberdyne. The company has 139 active competitors, including 46 funded and 27 that have exited. Its top competitors include companies like Novozymes, Phathom Pharmaceuticals and OMass Therapeutics.

Company Details

Developer of probiotic medicines for gastrointestinal diseases. It has developed physiologically active substances derived from probiotics used for the treatment of inflammatory bowel disease (IBD). The company has discovered Lactobacillus Brevis derived poly P exhibited a beneficial function and can be used for the treatment of the disease.

Website: www.kamuipharma.co.jp/
Email ID: *****@kamuipharma.co.jp

Key Metrics

Founded Year

2018

Location

Asahikawa, Japan

Stage

Series B

Total Funding

$130M in 2 rounds

Latest Funding Round

Series B, Jul 26, 2022, $*****

Investors

Mitsubishi UFJ Capital & 4 more

Ranked

55^th among 139 active competitors

Similar Companies

Novozymes & 159 more

View Kamui Pharma's full profile

Kamui Pharma has raised a total funding of $130M over 2 rounds. Its first funding round was on 2018. Its latest funding round was a Series B round on Jul 26, 2022 for $*****. 5 investors participated in its latest round. Kamui Pharma has 4 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Kamui Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 26, 2022	6366946	Series B	8912769	3052226	2723312	1592468
2018	1243	Seed	8336	9125	Mitsubishi UFJ Capital	5528

Access funding benchmarks and valuations. Sign up today!

View details of Kamui Pharma's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kamui Pharma include Novozymes, Phathom Pharmaceuticals and OMass Therapeutics. Here is the list of Top 10 competitors of Kamui Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novozymes 2000, Bagsvaerd (Denmark), Acquired	Developer of biosolutions and enzymes for multiple industries and applications of biotechnology	$9.75M	DOE, CHV & 3 others	73/100
2nd	Phathom Pharmaceuticals 2019, Menlo Park (United States), Public	Developer of therapies for treating gastrointestinal diseases	$90M	Frazier Healthcare Partners, BVF Partners ... & 12 others	66/100
3rd	OMass Therapeutics 2016, Oxford (United Kingdom), Series B	Developer of therapeutics for immunological and orphan diseases	$166M	Northpond Ventures, Sanofi Ventures & 6 others	65/100
4th	Enveda 2019, Boulder (United States), Series E	AI-based platform to decipher the chemistry of nature and develop new medicines	$845M	Premji Invest, Kinnevik & 36 others	63/100
5th	Kanvas Biosciences 2021, Ithaca (United States), Series A	Provider of imaging solutions for microbial research and infectious diseases	$77.5M	DCVC, Uncommon Denominator & 11 others	63/100
6th	Samsung Bioepis 2012, Incheon (South Korea), Acquired	Developer of biosimilar drugs for the treatment of multiple diseases	-	Biogen, Samsung BioLogics	63/100
7th	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Mayo Clinic Business Accelerator ... & 8 others	60/100
8th	Emmaus Medical 2000, Torrance (United States), Acquired	Developer of small molecule therapeutics for the treatment of sickle cell anemia and sickle ß0-thalassemia	-	E&Investment, Mitsubishi UFJ Capital & 4 others	60/100
9th	Infinant Health 2011, Norwalk (United States), Series C	Microbiome-based products to improve infant immune system	$39.2M	iSelect Fund, Gates & 4 others	60/100
10th	Accropeutics 2017, Suzhou (China), Series C	Developer of drugs for inflammation, autoimmune diseases, and cancer	$62M	Orbimed, Shenzhen Capital Group & 7 others	59/100
55th	Kamui Pharma 2018, Asahikawa (Japan), Series B	Developer of probiotic medicines for gastrointestinal diseases	$130M	Hokkaido Venture Capital, DG Ventures & 3 others	39/100